SI1814595T1 - Zdravljenje raka s kombinacijo sredstva, ki moti EGF signalno pot, in oligonukleotida, ki zniĹľuje nivoje klusterina - Google Patents

Zdravljenje raka s kombinacijo sredstva, ki moti EGF signalno pot, in oligonukleotida, ki zniĹľuje nivoje klusterina

Info

Publication number
SI1814595T1
SI1814595T1 SI200531838T SI200531838T SI1814595T1 SI 1814595 T1 SI1814595 T1 SI 1814595T1 SI 200531838 T SI200531838 T SI 200531838T SI 200531838 T SI200531838 T SI 200531838T SI 1814595 T1 SI1814595 T1 SI 1814595T1
Authority
SI
Slovenia
Prior art keywords
perturbs
oligonucleotide
cancer
agent
treatment
Prior art date
Application number
SI200531838T
Other languages
English (en)
Inventor
Martin Gleave
Gabriella Zupi
Original Assignee
The University Of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University Of British Columbia filed Critical The University Of British Columbia
Publication of SI1814595T1 publication Critical patent/SI1814595T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
SI200531838T 2004-11-23 2005-11-22 Zdravljenje raka s kombinacijo sredstva, ki moti EGF signalno pot, in oligonukleotida, ki zniĹľuje nivoje klusterina SI1814595T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US52294804P 2004-11-23 2004-11-23
US52296004P 2004-11-24 2004-11-24
PCT/CA2005/001775 WO2006056054A1 (en) 2004-11-23 2005-11-22 Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels
EP05810600.6A EP1814595B1 (en) 2004-11-23 2005-11-22 Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels

Publications (1)

Publication Number Publication Date
SI1814595T1 true SI1814595T1 (sl) 2014-06-30

Family

ID=36497699

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200531838T SI1814595T1 (sl) 2004-11-23 2005-11-22 Zdravljenje raka s kombinacijo sredstva, ki moti EGF signalno pot, in oligonukleotida, ki zniĹľuje nivoje klusterina

Country Status (11)

Country Link
US (2) US20080014198A1 (sl)
EP (1) EP1814595B1 (sl)
JP (1) JP4980919B2 (sl)
AU (1) AU2005309274B2 (sl)
CA (1) CA2584646C (sl)
DK (1) DK1814595T3 (sl)
ES (1) ES2456017T3 (sl)
PL (1) PL1814595T3 (sl)
PT (1) PT1814595E (sl)
SI (1) SI1814595T1 (sl)
WO (1) WO2006056054A1 (sl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1163254T3 (da) 1999-02-26 2008-06-09 Univ British Columbia TRPM-2 antisense-behandling
US7569551B2 (en) * 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
WO2005094899A1 (en) 2004-04-02 2005-10-13 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
AU2005309274B2 (en) * 2004-11-23 2011-07-21 The University Of British Columbia Treatment of cancer with a combination of an agent that perturbs the EGF signaling pathway and an oligonucleotide that reduces clusterin levels
JP5376948B2 (ja) 2005-09-13 2013-12-25 ナショナル リサーチ カウンシル オブ カナダ 腫瘍細胞活性を調節する方法及び組成物
US8802826B2 (en) 2009-11-24 2014-08-12 Alethia Biotherapeutics Inc. Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
AU2012228010B2 (en) 2011-03-15 2016-08-25 The University Of British Columbia Combination of anti-clusterin oligonucleotide with Hsp90 inhibitor for the treatment of prostate cancer
JP2015512877A (ja) 2012-02-22 2015-04-30 アレシア・バイオセラピューティクス・インコーポレーテッド 癌を治療するためのクラステリン阻害剤とｅｇｆｒ阻害剤の併用
MD20140101A2 (ro) * 2013-02-22 2015-02-28 Alethia Biotherapeutics Inc. Utilizarea concomitentă a unui inhibitor al clusterinei cu un inhibitor al EGFR pentru tratamentul cancerului

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
US5417978A (en) * 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
EP0736093B1 (en) * 1993-12-23 2003-03-19 BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH ANTISENSE NUCLEIC ACIDS FOR THE PREVENTION AND TREATMENT OF DISORDERS IN WHICH EXPRESSION OF c-erbB-2 PLAYS A ROLL
AUPM672594A0 (en) * 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
US5789389A (en) * 1995-03-17 1998-08-04 Board Of Trustees Of University Of Illinois BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
EP0882061B1 (en) * 1996-02-14 2004-05-19 Isis Pharmaceuticals, Inc. Sugar-modified gapped oligonucleotides
US5910583A (en) * 1996-11-04 1999-06-08 Duke University Antisense oligonucleotides against ERBB-2
US6383808B1 (en) 2000-09-11 2002-05-07 Isis Pharmaceuticals, Inc. Antisense inhibition of clusterin expression
US6335194B1 (en) * 1998-09-29 2002-01-01 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
US6172216B1 (en) * 1998-10-07 2001-01-09 Isis Pharmaceuticals Inc. Antisense modulation of BCL-X expression
US6900187B2 (en) * 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
DK1163254T3 (da) * 1999-02-26 2008-06-09 Univ British Columbia TRPM-2 antisense-behandling
US5998148A (en) * 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
US7569551B2 (en) * 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
US20030124513A1 (en) * 2001-05-29 2003-07-03 Mcswiggen James Enzymatic nucleic acid treatment of diseases or conditions related to levels of HIV
CA2469685C (en) * 2002-01-17 2013-03-12 The University Of British Columbia Bispecific antisense oligonucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
CA2485589A1 (en) * 2002-05-14 2003-11-27 Baylor College Of Medicine Small molecule inhibitors of her2 expression
JP4717633B2 (ja) * 2002-08-21 2011-07-06 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア 癌関連タンパク質を標的とするＲＮＡｉプローブ
US7285541B2 (en) * 2002-08-21 2007-10-23 The University Of British Columbia Treatment of melanoma by reduction in clusterin levels
US20040220131A1 (en) * 2003-04-18 2004-11-04 The University Of British Columbia Method for treatment of cancerous angiogenic disorders
CA2520518A1 (en) * 2003-04-18 2004-10-28 The University Of British Columbia Method for treatment of angiogenic disorders
WO2005094899A1 (en) * 2004-04-02 2005-10-13 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
AU2005309274B2 (en) * 2004-11-23 2011-07-21 The University Of British Columbia Treatment of cancer with a combination of an agent that perturbs the EGF signaling pathway and an oligonucleotide that reduces clusterin levels

Also Published As

Publication number Publication date
CA2584646C (en) 2015-11-03
US20110142827A1 (en) 2011-06-16
CA2584646A1 (en) 2006-06-01
JP2008520591A (ja) 2008-06-19
AU2005309274B2 (en) 2011-07-21
EP1814595A4 (en) 2009-04-15
WO2006056054A1 (en) 2006-06-01
ES2456017T3 (es) 2014-04-21
PL1814595T3 (pl) 2014-08-29
AU2005309274A1 (en) 2006-06-01
JP4980919B2 (ja) 2012-07-18
EP1814595B1 (en) 2014-01-08
PT1814595E (pt) 2014-04-02
EP1814595A1 (en) 2007-08-08
US20080014198A1 (en) 2008-01-17
DK1814595T3 (da) 2014-03-31

Similar Documents

Publication Publication Date Title
SI1814595T1 (sl) Zdravljenje raka s kombinacijo sredstva, ki moti EGF signalno pot, in oligonukleotida, ki zniĹľuje nivoje klusterina
IL185679A0 (en) Anti-proliferative combination therapy using certain platinum-based chemotherapeutic agents and taxanes
IL187898A0 (en) Parp modulators and treatment of cancer
IL190745A0 (en) Microangiopathy treatment and prevention
IL186662A0 (en) Combination cancer therapy with
EP1727498A4 (en) DEVICES AND METHODS FOR ENDOVASCULAR TREATMENT
PL1974579T3 (pl) Zlokalizowana i rozproszona transmisja
ZA200903173B (en) Cancer susceptibility variants on chr8q24.21
EP1786515A4 (en) TREATMENT OF THE VEGETABLE NERVOUS SYSTEM
IL182533A0 (en) Prostate treatment stent
EP1804891A4 (en) CAVITATION-IMPROVED TREATMENT THROUGH LOCAL LEVY
HK1125156A1 (en) Webbing and tear-away webbing
WO2004103301A3 (en) Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
EP1756166A4 (en) DIAGNOSIS AND TREATMENT OF PROSTATE CANCER
IL209361A0 (en) Combination therapy with pm00104 and another antitumor agent
ZA200610032B (en) Oculoselective drugs and prodrugs
HK1128234A1 (en) Combination comprising combretastatin and anticancer agents
GB0417481D0 (en) Combination therapy
EP1789064A4 (en) IMPROVED CANCER TREATMENT
EP1817039A4 (en) TREATMENT AND PREVENTION OF EPILEPSY
AP2007004024A0 (en) Therapeutic pyrazoloÄ3,4-BÜpyridines and indazoles
ZA200709542B (en) Combination therapy in the treatment of cancer
GB0428187D0 (en) Cancer treatment
IL178401A0 (en) USE OF ANTISENSE OLIGONUCLEOTIDES AGAINST cPLA2 IN THE TREATMENT OF CANCER
GB0428170D0 (en) Mono and Combination Therapy